Skip to content
AnalystLens

Neurocrine Biosciences 8-K Report, Corporate Update (Nov 1, 2024)

Reports
Other Events
Filing Date
Filed November 1, 2024
Period End
October 31, 2024
Security
NBIX
In the record · 2016–202610-K1210-Q338-K128

NBIX filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 128 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jan ’19Jan ’19
  2. Leadership change8-K · May ’22May ’22
  3. Leadership change8-K · Sep ’26Sep ’26

Summary

Summary of the 8-K filed November 1, 2024. Cited figures are marked; the original filing is the authoritative source.

Neurocrine Biosciences, Inc. reported in this Form 8-K, filed November 1, 2024, that on October 31, 2024 it entered into an accelerated share repurchase (ASR) agreement with Goldman Sachs & Co. LLC to repurchase $300.00 milliona of its common stock.

The ASR is being completed under a previously announced $300.00 millionb share repurchase program authorized by the Board of Directors. Under the ASR Agreement, the company will pay the $300.00 million Repurchase Price on November 4, 2024 and receive common stock with an aggregate value equal to 80% of that price, based on the October 31, 2024 closing share price. The final number of shares will be based on volume-weighted average prices over the transaction term, less a discount, subject to adjustments.

At final settlement, Neurocrine may receive additional shares from Goldman Sachs or, in certain circumstances, may have to deliver shares or make a cash payment at its option. The ASR agreement includes customary provisions, including adjustment, acceleration, extension and early termination terms, along with representations and warranties. The transaction is scheduled to terminate in the first quarter of 2025.

Key Highlights

  1. Entered an accelerated share repurchase agreement with Goldman Sachs & Co. LLC on October 31, 2024
  2. Repurchase size is $300.00 million of common stock (par value $0.001 per share)
  3. Transaction is being completed under a previously announced $300.00 million Board-authorized repurchase program
  4. Company pays the Repurchase Price on November 4, 2024 and initially receives shares worth 80% of that price, based on the October 31, 2024 closing price
  5. Final share count depends on volume-weighted average prices over the term, less a discount, with possible true-up payments in either direction
  6. ASR transaction is scheduled to terminate in the first quarter of 2025

Frequently Asked Questions

  1. How much is Neurocrine Biosciences repurchasing under this ASR?

    The company is repurchasing an aggregate of $300.00 million of its common stock under the ASR agreement.

  2. What initial share delivery does the company receive?

    On November 4, 2024, the company receives common stock with an aggregate value of 80% of the $300.00 million Repurchase Price, based on the October 31, 2024 closing share price.

  3. How is the final number of shares determined?

    The total shares repurchased are based on volume-weighted average prices of the common stock during the ASR term, less a discount and subject to the agreement's adjustments.

  4. Could Neurocrine owe additional shares or cash at settlement?

    At final settlement, the company may receive additional shares from Goldman Sachs & Co. LLC or, under certain circumstances, may be required to deliver shares or make a cash payment, at its option, to Goldman Sachs.

  5. When does the ASR transaction end?

    The ASR transaction is scheduled to terminate in the first quarter of 2025.